![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
LL von Moltke, DJ Greenblatt, MM Cotreau-Bibbo, SX Duan, JS Harmatz and RI Shader
Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Massachusetts.
Biotransformation of the tricyclic antidepressant desipramine (DMI) to its metabolite 2-hydroxy-desipramine (2-OH-DMI) was studied in vitro using microsomal preparations from human, monkey, mouse and rat liver. In all species 2-OH-DMI was the principal identified metabolite. Mean (+/- S.E.) reaction parameters in six human liver samples were: Vmax, 0.11 +/- .02 nmol/ml/min/mg protein; Km, 16.1 +/- 4.2 microM. Quinidine was a highly potent inhibitor of 2-OH-DMI formation (mean Ki = 0.053 microM), consistent with the presumed role of Cytochrome P450-2D6 in mediating this reaction. Ketoconazole was a much less potent inhibitor (mean Ki = 10.3 microM). Two serotonin-specific reuptake inhibitor (SSRI) antidepressants, and their respective metabolites, were evaluated as potential inhibitors of 2-OH-DMI formation. Fluoxetine (FLU) and norfluoxetine (NOR) were the most potent inhibitors (mean Ki values: 3.0 and 3.5 microM, respectively). Sertraline (SERT) and its metabolite desmethylsertraline (DES) also inhibited the reaction (mean Ki: 22.7 and 16.0 microM), but were significantly less potent than FLU or NOR. Values of Ki and Km measured in vitro were used to generate a theoretical prediction of the degree of clearance inhibition in vivo at any given concentration of substrate and inhibitor. The model was applied to a clinical study in which DMI clearance in humans was impaired by coadministration of FLU (yielding FLU and NOR in plasma) or by SERT (yielding SERT and DES in plasma). Use of plasma SSRI concentrations in the predictive model underestimated the actual impairment of DMI clearance.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  H. S. Brown, A. Chadwick, and J. B. Houston Use of Isolated Hepatocyte Preparations for Cytochrome P450 Inhibition Studies: Comparison with Microsomes for Ki Determination Drug Metab. Dispos., November 1, 2007; 35(11): 2119 - 2126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Gibbs, R. Hyland, and K. Youdim Minimizing Polymorphic Metabolism in Drug Discovery: Evaluation of the Utility of in Vitro Methods for Predicting Pharmacokinetic Consequences Associated with CYP2D6 Metabolism Drug Metab. Dispos., September 1, 2006; 34(9): 1516 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Obach, R. L. Walsky, K. Venkatakrishnan, E. A. Gaman, J. B. Houston, and L. M. Tremaine The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 336 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Jones, D. Hallifax, and J. B. Houston QUANTITATIVE PREDICTION OF THE IN VIVO INHIBITION OF DIAZEPAM METABOLISM BY OMEPRAZOLE USING RAT LIVER MICROSOMES AND HEPATOCYTES Drug Metab. Dispos., May 1, 2004; 32(5): 572 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Greenblatt, L. L. von Moltke, J. S. Harmatz, S. M. Fogelman, G. Chen, J. A. Graf, P. Mertzanis, S. Byron, K. E. Culm, B. W. Granda, et al. Short-Term Exposure to Low-Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone J. Clin. Pharmacol., April 1, 2003; 43(4): 414 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Bertelsen, K. Venkatakrishnan, L. L. von Moltke, R. S. Obach, and D. J. Greenblatt Apparent Mechanism-based Inhibition of Human CYP2D6 in Vitro by Paroxetine: Comparison with Fluoxetine and Quinidine Drug Metab. Dispos., March 1, 2003; 31(3): 289 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Tran, L. L. von Moltke, K. Venkatakrishnan, B. W. Granda, M. A. Gibbs, R. S. Obach, J. S. Harmatz, and D. J. Greenblatt Microsomal Protein Concentration Modifies the Apparent Inhibitory Potency of CYP3A Inhibitors Drug Metab. Dispos., December 1, 2002; 30(12): 1441 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Venkatakrishnan, L. L. von Moltke, M. H. Court, J. S. Harmatz, C. L. Crespi, and D. J. Greenblatt Comparison between Cytochrome P450 (CYP) Content and Relative Activity Approaches to Scaling from cDNA-Expressed CYPs to Human Liver Microsomes: Ratios of Accessory Proteins as Sources of Discrepancies between the Approaches Drug Metab. Dispos., April 13, 2001; 28(12): 1493 - 1504. [Abstract] [Full Text]
|
|
|
|
|
|
K. Venkatakrishnan, L. L. von Moltke, and D. J. Greenblatt Application of the Relative Activity Factor Approach in Scaling from Heterologously Expressed Cytochromes P450 to Human Liver Microsomes: Studies on Amitriptyline as a Model Substrate J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 326 - 337. [Abstract] [Full Text]
|
|
|
|
|
|
L. M. Hesse, K. Venkatakrishnan, L. L. von Moltke, R. I. Shader, and D. J. Greenblatt CYP3A4 Is the Major CYP Isoform Mediating the in Vitro Hydroxylation and Demethylation of Flunitrazepam Drug Metab. Dispos., February 1, 2001; 29(2): 133 - 140. [Abstract] [Full Text]
|
|
|
|
|
|
K. Venkatakrishnan, L. L. von Moltke, R. S. Obach, and D. J. Greenblatt Microsomal Binding of Amitriptyline: Effect on Estimation of Enzyme Kinetic Parameters In Vitro J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 343 - 350. [Abstract] [Full Text]
|
|
|
|
|
|
S.-i. Kuriya, S. Ohmori, M. Hino, I. Ishii, H. Nakamura, C. Senda, T. Igarashi, M. Kiuchi, and M. Kitada Identification of Cytochrome P-450 Isoform(s) Responsible for the Metabolism of Pimobendan in Human Liver Microsomes Drug Metab. Dispos., January 1, 2000; 28(1): 73 - 78. [Abstract] [Full Text]
|
|
|
|
|
|
K. Kobayashi, T. Ishizuka, N. Shimada, Y. Yoshimura, K. Kamijima, and K. Chiba Short Communication: Sertraline N-Demethylation Is Catalyzed by Multiple Isoforms of Human Cytochrome P-450 In Vitro Drug Metab. Dispos., July 1, 1999; 27(7): 763 - 766. [Abstract] [Full Text]
|
|
|
|
|
|
X.-J. Zhao, E. Koyama, and T. Ishizaki An In Vitro Study on the Metabolism and Possible Drug Interactions of Rokitamycin, a Macrolide Antibiotic, Using Human Liver Microsomes Drug Metab. Dispos., July 1, 1999; 27(7): 776 - 785. [Abstract] [Full Text]
|
|
|
|
|
|
E. Ludwig, J. Schmid, K. Beschke, and T. Ebner Activation of Human Cytochrome P-450 3A4-Catalyzed Meloxicam 5'-Methylhydroxylation by Quinidine and Hydroquinidine In Vitro J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 1 - 8. [Abstract] [Full Text]
|
|
|
|
|
|
C. Iribarne, F. Berthou, D. Carlhant, Y. Dreano, D. Picart, F. Lohezic, and C. Riche Inhibition of Methadone and Buprenorphine N-Dealkylations by Three HIV-1 Protease Inhibitors Drug Metab. Dispos., March 1, 1998; 26(3): 257 - 260. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. J. Goodnick and B. J. Goldstein Selective serotonin reuptake inhibitors in affective disorders -- I. Basic pharmacology J Psychopharmacol, January 1, 1998; 12(4_suppl): 5 - S20. [Abstract] [PDF]
|
|
|
|
|
|
K. Ito, D. Hallifax, R. S. Obach, and J. B. Houston IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM Drug Metab. Dispos., June 1, 2005; 33(6): 837 - 844. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
